Thromb Haemost 1995; 73(04): 668-674
DOI: 10.1055/s-0038-1653838
Original Articles
Coagulation
Schattauer GmbH Stuttgart

Differences in the Interactions of Lupus Anticoagulant IgG with Human Prothrombin and Bovine Prothrombin

L Vijaya Mohan Rao
1   The Department of Biochemistry, The University of Texas Health Center at Tyler, Tyler, TX, USA
,
An D Hoang
2   The Department of Medicine, University of California, San Diego, La Jolla, CA, USA
,
Samuel I Rapaport
2   The Department of Medicine, University of California, San Diego, La Jolla, CA, USA
› Author Affiliations
Further Information

Publication History

Received 04 October 1994

Accepted after revision 05 December 1994

Publication Date:
09 July 2018 (online)

Summary

Lupus anticoagulant (LA) IgGs have been reported to inhibit more effectively and consistently the Xa/Va/phospholipid complex-catalyzed activation of human prothrombin than the Xa/Va/phospholipid complex-catalyzed activation of bovine prothrombin. This led us to carry out studies to determine whether the ability to inhibit the activation of prothrombin of LA IgGs, separated from the plasma of 15 patients by protein A affinity chromatography, could be related to the ability of the LA IgGs to bind to prothrombin under various experimental conditions. Of 14 LA IgG preparations tested all prolonged to a variable but substantial extent the dilute Russell’s viper venom time (dRVVT) of human plasma but only minimally prolonged the dRVVT of bovine plasma. In a purified prothrombin activation system with a rate limiting concentration of phospholipid, all 15 LA IgG preparations inhibited the activation of human prothrombin with the majority showing >50% of inhibition. In contrast, only one LA IgG markedly inhibited (>50%) the activation of bovine prothrombin and five others moderately inhibited (25-40%) the activation of bovine prothrombin. Nevertheless, the majority of LA IgG preparations bound to immobilized bovine prothrombin on a Western blot and also to immobilized bovine prothrombin on a microtiter well. In an ELISA in which phosphatidylserine (PS) was immobilized on microtiter wells, bovine prothrombin supported the binding of 10 of 15 LA IgG preparations to PS. However, the extent of binding was lower than that observed with human prothrombin. In experiments with 125I-human prothrombin or 125I-bovine prothrombin in a solution containing Ca2+, the addition of PS/PC vesicles enhanced the binding of both human and bovine prothrombin to some LA IgG preparations. The enhanced binding was particularly evident for bovine prothrombin. Although seemingly related for some preparations, the ability of a LA IgG to bind to bovine prothrombin, either in the presence or absence of PS, and the ability of that LA IgG to inhibit the activation of bovine prothrombin was not consistently related for all preparations.

 
  • References

  • 1 Loeliger A. Prothrombin as co-factor of the circulating anticoagulant in systemic lupus erythematosus. Thromb Diath Haemorrh 1959; 3: 237-256
  • 2 Edson JR, Vogt JM, Hasegawa DK. Abnormal prothrombin crossed-immu-noelectrophoresis in patients with lupus inhibitors. Blood 1984; 64: 807-816
  • 3 Fleck RA, Rapaport SI, Rao LV M. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988; 72: 512-519
  • 4 Permpikul P, Rao LV M, Rapaport SI. Functional and binding studies of the roles of prothrombin and β2-glycoprotein I in the expression of lupus anti-coagulant activity. Blood 1994; 83: 2878-2892
  • 5 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF A. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemostas 1991; 66: 629-632
  • 6 Galli M, Bevers EM, Comfurius P, Barbui T, Zwaal RF A. Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol 1993; 83: 466-472
  • 7 Mimms LT, Zampighi G, Nozaki Y, Tanford C, Reynolds JA. Phospholipid vesicle formation and transmembrane protein incorporation using octylglucoside. Biochem 1981; 20: 833-840
  • 8 Bajaj SP, Rapaport SI, Prodanos C. A simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem 1981; 11: 397-412
  • 9 Rao LV M, Robinson T, Hoang AD. Factor VIIa/tissue factor-catalyzed activation of factors IX and X on a cell surface and in suspension: A kinetic study. Thromb Haemostas 1992; 67: 654-659
  • 10 Kane WH, Majerus PW. Purification and characterization of human coagulation factor V. J Biol Chem 1981; 256: 1002-1007
  • 11 Almus FE, Rao LV M, Rapaport SI. Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model. Arterioscler Thromb 1993; 13: 105-111
  • 12 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 1970; 227: 680-685